Elsevier

International Journal of Drug Policy

Volume 47, September 2017, Pages 102-106
International Journal of Drug Policy

Research paper
Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia

https://doi.org/10.1016/j.drugpo.2017.07.008Get rights and content

Abstract

Background

People who inject drugs (PWID) often do not receive confirmatory RNA testing following positive HCV antibody testing. Expanding access to adequate testing and assessment will improve the progression of patients through the HCV care cascade with the potential to improve diagnosis as well as linkage to treatment. We aimed to determine current utilisation of general practitioners (GPs) by PWID in Australia compared to other settings for HCV testing and post-test discussions.

Methods

A national sample (n = 888) of people who had injected drugs regularly in the past 6 months was interviewed about HCV antibody, RNA testing, and post-test discussions, and the settings where these took place.

Results

The majority of participants (n = 735; 93%) reported antibody testing. Among participants who reported a positive result (n = 435), 54% identified their regular GP as the setting where their most recent antibody test was conducted. Confirmatory RNA testing was reported by 60% (n = 274) of those who reported being antibody positive. Among those who reported RNA testing (n = 257), the most common setting reported was their regular GP (48%). There were no differences in the proportions who recalled post-test discussions at GPs compared to other settings.

Conclusion

HCV testing was most frequently undertaken by participants' regular GP. GPs are currently providing testing and post-test discussions at similar proportions to other more specialised settings. However, RNA testing is incomplete for more than one-third of the antibody positive PWID interviewed. Our findings suggest that the general practice setting is a common and accessible setting for PWID to access HCV testing. Targeting GPs to improve follow-up of positive antibody tests may help to improve patient progression through the HCV care cascade.

Introduction

Chronic Hepatitis C remains a major source of morbidity and mortality. Globally chronic Hepatitis C affects about 70 million people (Blach et al., 2017). Within developed countries many of those affected are people who inject drugs (PWID) and comprise the largest affected group (Degenhardt et al., 2016).

Treatment uptake has been poor and more than 700,000 people die globally of HCV-related conditions each year (Lanini, Easterbrook, Zumla, & Ippolito, 2016). Many barriers exist that impact treatment uptake including patient-level, provider-level, and system-level barriers. Direct acting antivirals (DAA) are a significant clinical advance that promises to alleviate some of these barriers. Treatment is more efficacious (>90% cure), side effects are substantially reduced, and treatment time has been shortened (Dore, Ward, & Thursz, 2014; Kohli, Shaffer, Sherman, & Kottilil, 2014; Lam, Jeffers, Younoszai, Fazel, & Younossi, 2015).

Although DAAs will address some barriers, others remain. Poor uptake of testing and assessment, low pharmacy coverage stocking medications, low levels of GP training and confidence, long treatment service waiting times, and the effects of discrimination and stigma remain barriers, especially for PWID (Bruggmann, 2012; Doab, Treloar, & Dore, 2005; Harris & Rhodes, 2013; Hopwood & Treloar, 2013).

Appropriate testing has numerous benefits both for the individual tested and for public health. Antibody testing (anti-HCV) detects exposure to the virus. Confirmatory testing, also called HCV RNA testing, uses a PCR (polymerase chain reaction) test to detect chronic infection. Limited provision of appropriate confirmatory testing among people with hepatitis C antibodies is a major gap in the HCV cascade of care (Snow, Scott, Clothier, MacLachlan, & Cowie, 2016). Accurate detection of HCV followed by appropriate post-test discussion can effectively reduce transmission risk by educating people living with HCV on how to modify risk behaviours and improve health outcomes through early referral for management and/or treatment (Bruneau et al., 2014). Post-test discussion is guided by the type of test performed (antibody or RNA), and the setting of the testing/consultation (Australasian Society for HIV Medicine, 2012; Ghany, Strader, Thomas, & Seeff, 2009). Themes that should be discussed include providing information on further testing that may be required, next steps in staging the disease for those who are RNA positive, potential treatment options, and precautions that can be taken to reduce the risk of transmission and improve health outcomes (i.e. diet and alcohol intake) (Australasian Society for HIV Medicine, 2012).

The World Health Organisation has developed treatment targets for the Global Health Sector Strategies for HIV, viral hepatitis, STIs, 2016–2021. These goals include reducing new cases by 90% (2030), and reducing mortality by 65% (2030). Key to achieving these goals will be targeting specific populations, in particular, PWID. Among developed countries, PWID are most at risk for contracting and transmitting the disease (Hajarizadeh, Grebely, & Dore, 2013). Providing treatment to this population will have significant impact upon reducing new cases (Martin, Vickerman et al., 2013).

Access to appropriate testing remains an important aspect of reaching PWID. Current efforts to increase testing within the opioid substitution therapy (OST) setting will reach some PWID, but not all. Australia has high coverage of OST (Mathers et al., 2010) but even so, in a sentinel sample of PWID up to one-third may not be eligible for OST and hence not come into contact with those services (Butler et al., 2015, Larney et al., 2016).

While much research has focused on investigating HCV care in OST in Australia and abroad, very little exists regarding HCV care in general practice (i.e. primary health care provider) settings. General practitioners (GPs) are typically easy to access, locally available, and where universal health care is available, are often free or low cost. Therefore, GP settings may be ideal for increasing access to appropriate HCV testing. We aimed to determine: 1. The proportion of PWID who accessed HCV antibody testing in the general practice setting; 2. The proportion of anti-HCV positive PWID who received confirmatory RNA testing in the GP setting compared to those tested at other sites (e.g. specialist, hospital, corrective services); and 3. What types of information PWID recall being given at time of diagnosis, and if this is different across sites.

Section snippets

Method

The Illicit Drug Reporting System (IDRS) is an annual illicit drug sentinel surveillance system conducted in every capital city in Australia. Methods are described in full elsewhere (Stafford & Breen, 2016). Briefly, a cross-sectional non-probability sample of PWID reporting at least monthly illicit drug injection in the preceding six months were recruited. They were reached through needle and syringe programs, peer referral, user representative groups, and street press advertising.

Results

Eight-hundred and eighty-eight participants were recruited. The sample had a mean age of 42 years (SD: 8.94; range 17–71), and 67% were male (Table 1).

Antibody testing was high, with 93% (n = 735) of the sample reporting having had at least one antibody test. Participants who reported antibody testing were significantly less likely (68% vs 88%, p = 0.002) to have completed year 10 of high school (the minimum level of schooling required in Australia), they were more likely to have a history of

Discussion

In this Australian sample of people who regularly inject drugs, HCV antibody testing was common, but RNA testing to confirm chronic infection was less so. This represents a missed opportunity for linking patients to treatment options, or at the bare minimum empowering patients with accurate information about their HCV status. Progression through the treatment cascade to linkage to care and treatment relies on appropriate testing. Improvement in testing will result in a flow on effect for

Limitations

Our study was based on a convenience sample of PWID. The population parameters of PWID are unknown, and it is therefore unclear whether the sample is representative of the broader PWID population. We relied on self-report, and data may therefore be limited by recall and social desirability bias. However, drug users’ self-report is considered sufficiently reliable and valid to provide descriptions of drug use-related problems (Darke, 1998). Although there are mixed data on the sensitivity of

Conclusions

Settings for HCV testing need to be broad and varied as no single model of care will suit everyone (Bruggmann & Litwin, 2013). GPs are typically easy to access, locally available and are already doing a large proportion of the testing for HCV among PWID in Australia. In terms of scaling up testing and treatment, increasing GP participation in HCV care will substantially grow the HCV workforce. Our findings suggest that the general practice setting is a common and accessible setting for PWID to

Funding

The Illicit Drug Reporting System Project was supported by funding from the Australian Government. The current paper design, conduct and interpretation of findings are the work of the investigators; theses funders had no role in this paper.

SL has received untied educational funding from Indivior.

Acknowledgements

The Illicit Drug Reporting System Project is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grants Fund. The current paper design, conduct and interpretation of findings are the work of the investigators; the funders had no role in this paper. The authors would like to acknowledge the contribution of collaborators from the following institutions; National Drug and Alcohol Research Centre — UNSW Australia, Queensland Alcohol and

References (41)

  • S. Blach et al.

    Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

    The Lancet Gastroenterology & Hepatology

    (2017)
  • P. Bruggmann

    Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers

    Journal of Viral Hepatitis

    (2012)
  • P. Bruggmann et al.

    Models of care for the management of hepatitis C virus among people who inject drugs: One size does not fit all

    Clinical Infectious Diseases

    (2013)
  • J. Bruneau et al.

    Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: A longitudinal study

    Clinical Infectious Diseases

    (2014)
  • B.L. Cullen et al.

    Identifying former injecting drug users infected with hepatitis C: An evaluation of a general practice-based case-finding intervention

    Journal of Public Health

    (2012)
  • C. Day et al.

    Experience of hepatitis C testing among injecting drug users in Sydney, Australia

    AIDS Care

    (2008)
  • A. Doab et al.

    Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia

    Clinical Infectious Diseases

    (2005)
  • G.J. Dore et al.

    Hepatitis C disease burden and strategies to manage the burden

    Journal of Viral Hepatitis

    (2014)
  • M.G. Ghany et al.

    Diagnosis, management, and treatment of hepatitis C: An update

    Hepatology

    (2009)
  • B. Hajarizadeh et al.

    Epidemiology and natural history of HCV infection

    Nature Reviews Gastroenterology and Hepatology

    (2013)
  • Cited by (16)

    • Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia

      2021, Journal of Substance Abuse Treatment
      Citation Excerpt :

      At the provider-level, study participants described experiences of stigma in healthcare settings hindering access to treatment. With research confirming general practice as common and accessible setting for PWID to seek DAA treatment (Butler et al., 2017), this study's findings support research suggesting more work is required to reduce stigma in general practice settings (Scarborough et al., 2017; Fenech et al., 2018; Wolfe et al., 2015). This must include addressing health and medical practitioner views of PWID as untrustworthy and/or chaotic, as well as increasing practitioner knowledge around the eligibility of current injecting drug users for DAA treatment and evidence demonstrating PWID have DAA treatment outcomes comparable to non-injecting drug users (Crawford & Bath, 2013; Read et al., 2017).

    • Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all

      2019, International Journal of Drug Policy
      Citation Excerpt :

      Homeless people who inject drugs may have a particularly high burden of HCV infection, with HCV antibody prevalence ranging from 55 to 81% (Strehlow et al., 2012). Unstable housing/homelessness has also been demonstrated to be associated with lower uptake of HCV testing and/or treatment (Butler et al., 2017). Two studies in the issue report on models of care to enhance the treatment of HCV in people who are homeless.

    • Elimination of Hepatitis C Virus in Australia: Laying the Foundation

      2018, Infectious Disease Clinics of North America
      Citation Excerpt :

      HCV education and training for primary care and addiction medicine physicians from the early 2000s has facilitated high levels of screening, and laid the foundation for the current major involvement of these groups in DAA prescribing.8 The broad implementation of harm reduction strategies for people who inject drugs (PWID), from the early 1990s, maintained a low prevalence of human immunodeficiency virus (HIV) infection (around 1% among PWID),10 prevented many HCV infections11 (although the chronic HCV prevalence was 45% before the DAA scale-up),12 and provided the public health interface to enable a highly marginalized population to have high levels of HCV screening (around 90%).12,13 Finally, as with the HIV response in Australia, bipartisan support (from both major political parties) and political leadership have been crucial to the development of HCV public health strategies that are pragmatic, highly cost effective, and generally well-accepted by the broader community.

    View all citing articles on Scopus
    View full text